April 16, 2023 Quthero’s Clinical Trial and Results presented at 2023 American Society for Laser Medicine and Surgery, Conference
Quthero is pleased to announce the presentation of its multi-site, split-face double-blinded clinical trial and results with its proprietary Q-peptide products following aesthetics procedures at the American Society for Laser Medicine and Surgery taking place in Phoenix, Arizona https://www.aslms.org/annual-conference-2023.
Dr. Catherine DiGiorgio of CMD Dermatology, Laser & Aesthetics in Boston who was one of the PI’s in the clinical trial, presented the results.
ASLMS is in its fifth decade as a world leader in promoting excellence in patient care by advancing biomedical application of lasers and energy-based technologies.
January 27, 2023 Quthero presents at 2023 Aesthetics Tech Forum
Quthero is pleased to announce its presentation at an invitation-only session titled “Partnership Pursuits” on Thursday Jan 27th taking place at the Octane’s Aesthetics Tech Forum in Newport Beach, CA https://octaneoc.org/aesthetics-tech-forum/.
This Forum is a curation of the best ideas, experts, startups, and learnings in latest aesthetics technologies. Please join our CBO, Karen Cronholm, as she presents the latest on Quthero’s post-procedure products and highlights opportunities to work with Quthero.
January 26, 2023 Q-gel preclinical studies and initial clinical trial results presented at 2023 John A. Boswick Burn and Wound Symposium
Quthero is pleased to announce the presentation of pre-clinical studies with its proprietary Q-gel and clinical trial results at the John A. Boswick Burn and Wound Symposium taking place at Wailea Beach Resort, Maui, Hawaii. https://jabmauisymposium.com/.
Dr. Dennis Orgill of Harvard Medical School and Brigham and Women’s Hospital will present the work at 10:45 am on Thursday, January 26th, 2023 in a presentation titled: “QHREDGS peptide modified hydrogel accelerates wound healing in pre-clinical small and large animal models paving a way to human dermatological and surgical trial”.
January 9, 2023 Quthero attends 2023 Biotechnology Showcase at JPM week in San Francisco
Quthero is pleased to announce the opportunities to partner during the upcoming JPM week in San Francisco as our CEO, Dr. Milica Radisic, attends Biotechnology Showcase, the investor conference for innovators. Quthero thanks the Government of Ontario for its support of this opportunity. https://informaconnect.com/biotech-showcase/
December 8, 2023 Quthero exceeds the first closing of its Series A round
Quthero is pleased to announce the first closing of its Series A round led by Boston Harbour Angels. The funds will be used to support the launch of its dermatological post-procedure products and the establishment of a surgical trial.
Join Quthero in congratulating our CEO, Dr. Milica Radisic, on being elected a Fellow of the Biomedical Engineering Society.
BMES serves as the lead society and professional home for biomedical engineers and bioengineers. The BMES Grade of Fellow is a professional distinction granted by the Board of Directors to a BMES member who has demonstrated impactful achievements and has made significant contributions to the biomedical engineering community.
September 16, 2022 Quthero to present at the RESI Boston Innovator’s Pitch Challenge
Join Quthero at the RESI Boston Conference as we pitch at the Innovator’s Pitch Challenge.
Life Science Nation’s RESI (Redefining Early Stage Investments) is an ongoing conference series establishing a global circuit for early stage life sciences companies to source investors, create relationships, and eventually, get funding. The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage life science and healthcare companies to gain additional exposure to conference attendees and pitch directly to a panel of judges, featuring active investors and industry experts.
August 31, 2022 Quthero welcomes Karen Cronholm as Chief Business Officer
Join Quthero in welcoming Karen Cronholm to the team as the Chief Business Officer.
Karen brings 25 years’ experience in the life sciences, medical device and aesthetics industries, most recently as CEO of Cytrellis Biosystems. She has a track record of launching exceptionally successful products and building commercial teams both at Cytrellis as well as Cynosure and EMD Millipore.
May 4 2022 Quthero launches Series A round led by Boston Harbor Angels
Quthero is looking to expand our team to include a VP Market Development – Clinical Skincare. Please see our posting on LinkedIn to apply.
Join Quthero in welcoming Kristin King, MBA, as Business Development Advisor to the team.
Kristin, currently the Vice President, Corporate Development & Strategy at Defibtech LLC, brings 25 years’ experience in corporate strategy, M&A and business development in medical devices and pharma.
Join Quthero in congratulating our CEO, Milica Radisic, as her first start-up, TARA Biosystems, is acquired by Valo Health.
TARA Biosystems uses tissue engineering to generate in vitro testing systems that mimic cardiac function and disease. These systems are used for drug discovery as an early predictor for drug safety and toxicity. Together with Valo, TARA’s platforms will revolutionize cardiovascular drug discovery.
Research conducted in Milica Radisic’s lab at the University of Toronto has identified Quthero’s technology as a possible treatment for COVID-19 infections. The technology has been demonstrated to prevent a cytokine storm, the life threatening immune reaction that has been associated with severe outcomes of COVID-19.
Quthero is excited to add another application to our platform technology.
February 9, 2022 Quthero to present at the OBIO Investment summit
Join Quthero at the OBIO Investment summit as we pitch to kick off our Series A Raise.
OBIO’s Investment summit brings together leading global investors, scientific experts and Canada’s most promising health science companies on February 9 to 11 (hosted virtually).
January 20, 2022 Quthero to present at Octane OC Aesthetics Tech Summit
Join Quthero at Octane OC Aesthetic Tech Summit where we will pitch our novel biomaterial solutions to disrupt skin care after dermatological procedures such as laser skin resurfacing & microneedling, and hear from other top leaders in the field of aesthetics.
January 10, 2022 Quthero receives medical device designation from Health Canada
In a pivotal decision, Quthero receives Class IV medical device designation for our novel biomaterials for acute donor site wound healing.
Join Quthero in congratulating our CEO, Milica Radisic, as the recipient of the 2022 Acta Biomaterialia Silver Medal. Milica is being recognized by Acta Biomaterialia for her contributions in the field of organ-on-a-chip engineering, and hydrogel and polymeric development. Through her research, she has founded two companies. Her first, TARA Biosystems, and her second being Quthero.
November 12, 2021 Quthero welcomes Stephen Whitehead and Wendy Hill as advisors
Join Quthero in welcoming Stephen Whitehead and Wendy Hill as Business and Regulatory Advisors to the team.
Stephen Whitehead brings 25 years of experience in product strategy, development and commercialization. He is a seasoned leader in the biotech sector and Quthero is enthralled to have Stephen join the team as a Business Advisor.
Wendy Hill has over 30 years of experience in regulatory affairs and clinical trial development in the fields of wound care, inflammation, cancer, and cardiovascular disease. Quthero is enthralled to have Wendy join the team as a Regulatory Advisor.
Join Quthero in welcoming Dr. Leonard Miller, Dr. Catherine DiGiorgio, and Dr. Omar Ibrahimi to the team.
Dr. Miller is Board certified by the American Board of Plastic Surgery and is the founder of the Boston Center for Facial Rejuvenation.
Dr. DiGiorgio is a board-certified dermatologist and Harvard trained laser and cosmetic dermatologist, currently practicing out of the Boston Center for Facial Rejuvenation.
Dr. Ibrahimi is a board certified Dermatologist and he is the founding and medical director of the Connecticut Skin Institute.
Quthero is excited to welcome their expertise and partner with them on future clinical trials.